Navigation Links
EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
Date:6/3/2011

mor cancers, leukemia, and multiple myeloma.  While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

To view a copy of the presentation, visit the Company's website at www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital an
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
2. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
5. New Published Study Demonstrates the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring in Patients in Surgery and Intensive Care
6. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
7. Dune Medicals MarginProbe™ Demonstrates Increased Positive Margin Identification Leading to Reduction in Patients Indicated for Re-excision in Landmark Lumpectomy Surgery Trial
8. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
9. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
10. Capasso lab demonstrates highly unidirectional whispering gallery microlasers
11. Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss of Lung Tissue in Patients with AAT-deficiency-related Emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... the launch of the FBRM® C35, designed to ... ... ... probe-based FBRM (Focused Beam Reflectance Measurement) technology the ...
... systems in product design and development, manufacture, ... ... Md., Oct. 1 Cylex has announced receipt of,certification ... with the Canadian Medical Devices Conformity Assessment,System (CMDCAS). These ...
... Million Strategic Investment in PharmAthene, ANNAPOLIS, Md., ... a biodefense company developing medical countermeasures,against biological and ... a strategic alliance with Panacea Biotec Ltd., that ... Biotec, through its,subsidiary, Kelisia Holdings Ltd., of $13.1 ...
Cached Biology Technology:Monitor Granule Growth in Process with the FBRM C35 2Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications 2PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases 2PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases 3PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases 4PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases 5
(Date:8/29/2014)... . The ... oldest form of communication. Acting as messenger molecules, pheromones ... attraction between males and females. Fish rely on pheromones ... in males and females. Scientists at the Marine Science ... Portugal, and at the Max Planck Institute for Chemical ...
(Date:8/29/2014)... USA - The rise of the Tibetan plateau -- ... -- is important for both its profound effect on ... study published in GSA Bulletin , Katharine Huntington ... isotope thermometry -- using modern and fossil snail shells ... in southwestern Tibet. , Views range widely on ...
(Date:8/28/2014)... new study reports that an expansion of marine protected ... key ecological functions. According to investigators from the ... protecting fish have focused on saving the largest numbers ... that provide key and difficult-to-replace ecological functions. ... performed by fish species that also are food for ...
Breaking Biology News(10 mins):Ready for mating at the right time 2Ready for mating at the right time 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... top student prize at the SCINEMA Festival of Science Film ... one of several Australian filmmakers whose films garnered awards from ... New Zealand during National Science Week (August 15 23). ... Science Week at Questacon in Canberra this morning. ...
... Cambridge, Mass. August 12, 2009 A multidisciplinary ... received a $10 million National Science Foundation (NSF) Expeditions ... mobile robotic devices. Inspired by the biology of a ... to push advances in miniature robotics and the design ...
... flu vaccine trials, led by the University of Leicester and ... the Leicester Royal Infirmary. Dr Iain Stephenson, a consultant ... at the University, has been carrying out research into swine ... Now he is working with 175 volunteers, aged 18-50, as ...
Cached Biology News:Australian filmmakers are stars of science film awards 2Harvard research team receives $10M NSF grant to develop small-scale mobile robotic devices 2Harvard research team receives $10M NSF grant to develop small-scale mobile robotic devices 3Harvard research team receives $10M NSF grant to develop small-scale mobile robotic devices 4Britain's first swine-flu trials under way 2
Request Info...
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
Spaced cover glasses to promote effective hybridization...
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
Biology Products: